Liver disease in injection drug users with hepatitis C, with and without HIV coinfection.

摘要: Liver disease is a major health problem for individuals with history of injection drug use. This mainly from the hepatitis C virus (HCV), or without co-infection HIV. HCV-associated liver takes decades to develop into cirrhosis, which it can adversely affect health. HIV coinfection among factors that are often associated progression, and efforts understand progression in HIV-HCV coinfected patients remain important. Maintaining high CD4 counts avoiding alcohol intake slower progression. Pegylated interferon ribavirin combination therapy has potential clear HCV, provides strongest benefit affected by virus, although this be difficult accomplish many reasons. Steatosis, fat within liver, may also have important pathological implications related HCV. Limiting IDUs well best accomplished through promoting their full utilization care.